Drugs / Pegtibatinase
Pegtibatinase
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT06431893 | Apr 2024 → Aug 2030 expected | homocystinuria | Travere Therapeutics, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06247085 | Dec 2023 → Aug 2027 expected | classic homocystinuria | Travere Therapeutics, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03406611 Comparator | Jan 2019 → Jun 2026 overdue | homocystinuria | Travere Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegtibatinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03406611 ↗ |
| Known as | 20nhs peg-cbs | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297799 ↗ |
| Known as | OT-58 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297799 ↗ |
| Known as | TVT-058 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297799 ↗ |
| Modality | Protein / enzyme biologic | “modified version of the native, human CBS (hCBS) enzyme” NCT03406611 ↗ |
| Route | Subcutaneous | “Pegtibatinase sterile solution for subcutaneous injection” NCT03406611 ↗ |